A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Gilead Sciences
St. Jude Children's Research Hospital
Allogene Therapeutics
Allogene Therapeutics
Allogene Therapeutics
Lyell Immunopharma, Inc.
M.D. Anderson Cancer Center
Senti Biosciences